Long-awaited results from the Herald study are a bust, and the data will likely deteriorate further.
Biogen’s Aduhelm was the big one, but there are plenty of other key regulatory decisions still pending this year.
Lynparza could become the first Parp inhibitor approved for adjuvant use, an Asco late-breaker reveals.
Awaiting crucial pivotal data, company reckons its plant-generated Covid-19 vaccine can still make a contribution to the pandemic.
With a Darpin antiviral for treating Covid-19 Molecular Partners hopes to follow Vir’s regulatory path.
As Covid-19 spending pushes the sector’s R&D bill ever higher, Lilly continues to plough the most back in as Sanofi applies the brakes.